Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis

April W. Armstrong; Mark Lebwohl; Akihiko Asahina; Ranga Gogineni; Christopher Em Griffiths

doi:10.1093/bjd/ljaf171

Abstract

1 min read

Treatment with tildrakizumab was effective with no safety signals found in either of the patient subgroups. Patients with late-onset psoriasis were more likely to achieve complete or near-complete clearance than patients with early-onset psoriasis.

Related publications

Article2025

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity

Mark Lebwohl, Jerry Bagel, Ranga Gogineni, Christopher Em Griffiths

Article2020

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp

Letter2015

Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis

Christopher Em Griffiths, Enno Christophers, Annette Szumski, Heather Jones, Lotus Mallbris

Article2014

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Giampiero Girolomoni, Christopher Em Griffiths, James G. Krueger, Frank O. Nestlé, Jean‐François Nicolas, JC Prinz, L. Puig, Mona Ståhle, P.C.M. van de Kerkhof, Matthieu Allez, Paul Emery, C. Paul

Article2008

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Jean‐Paul Ortonne, Christopher Em Griffiths, E. Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, C. Molta, Bruce Freundlich